An early Parkinson's diagnosis: what it could mean for care, and what it doesn't

Richard Moore
19 hours ago
18 min read

The moment a neurologist says "Parkinson's disease," time seems to stop. The word lands like a stone dropped into still water, heavy, radiating outward into every corner of a life. But here is what that neurologist almost certainly didn't have the time to tell you, and what the emerging science is now saying clearly: what happens next is not determined by the diagnosis alone. How you eat, move, sleep, and support your gut health all interact with the biology of Parkinson's disease in ways that are measurable, documented, and worth understanding.

This is not a promise of cure. No honest science writer, nutritional therapist, or neurologist will make you that promise. What this piece offers instead is something more durable: evidence. Evidence that the choices you make about food, movement, sleep, and gut health can influence how you feel, how your non-motor symptoms behave, and how well you function alongside Parkinson's disease, and that starting those choices early is worth every effort.

A diagnosis is not a destiny. But you deserve to know exactly what the science says about shaping what comes next.

Before the tremor: your body was already sending signals

The motor symptoms that typically prompt a Parkinson's diagnosis (tremor, rigidity, slowness) are, in biological terms, late arrivals. Neuroscience now knows that what is called the prodromal phase of Parkinson's can precede visible motor symptoms by years, sometimes by more than two decades.

Three signals in particular have drawn significant research attention. First, the loss of smell. Reduced or absent olfactory function, hyposmia, affects up to 90% of people with Parkinson's disease and is often present long before a diagnosis is made (Orso et al., 2024, Journal of Parkinson's Disease). Second, chronic constipation, which studies suggest can precede a Parkinson's diagnosis by 10 to 20 years (Schrag et al., 2015, The Lancet Neurology). Third, REM sleep behaviour disorder, a condition in which the normal muscle paralysis of dream sleep fails, causing a person to physically act out their dreams. Research has found that confirmed REM sleep behaviour disorder carries a positive likelihood ratio of 130 for future Parkinson's disease, an extraordinary predictive signal (Orso et al., 2024).

It is important to be clear: these symptoms are not a diagnosis. Loss of smell, disturbed sleep, and constipation each have many causes unrelated to Parkinson's. But their co-occurrence, particularly alongside family history or other risk factors, is a meaningful cluster that warrants specialist discussion.

Why does this matter for people already diagnosed? Because it reshapes how we understand the disease timeline. You are not at the beginning of something that started at diagnosis. You are, likely, further along a longer arc, and that means earlier action, including nutritional action, is more relevant than many standard consultations acknowledge.

What actually changes in the brain at early diagnosis

Inside the substantia nigra, a small, dense cluster of neurones deep in the midbrain, lives a population of cells that produce dopamine. These neurones regulate not just movement, but motivational drive and the fluid, automatic coordination of physical action. When Parkinson's disease develops, this population comes under sustained attack.

The molecular mechanism involves a protein called alpha-synuclein. In healthy brains, alpha-synuclein remains soluble and performs normal functions. In Parkinson's disease, it misfolds and aggregates into toxic structures called Lewy bodies, which spread from cell to cell and trigger both mitochondrial dysfunction and chronic neuroinflammation (Frontiers in Aging Neuroscience, 2025). By the time a clinical diagnosis is made, a significant proportion of dopaminergic neurones in the substantia nigra have already been lost.

A separate and actively debated question is where the disease originates. A growing body of research suggests that in at least a subset of patients, misfolded alpha-synuclein may begin in the enteric nervous system of the gut and travel upward along the vagus nerve to the brain, a theory sometimes called the "body-first" hypothesis (Menozzi et al., 2025, Movement Disorders Clinical Practice). This is not confirmed. Parkinson's disease is now understood to be heterogeneous, meaning different people may experience different biological subtypes with different starting points. But the gut-origin hypothesis is one reason the gut-brain axis has become one of the most active areas of Parkinson's research, and why gut health features so prominently in evidence-informed nutritional care.

What the remaining neurones in early Parkinson's disease are not is inert. They are metabolically active, responsive to their environment, and influenced by the biological conditions around them. This is where nutrition, exercise, and sleep enter the story.

What actually changes in the brain at early diagnosis

Why Parkinson's is rising, and what the environment has to do with It

The scale of what is happening globally deserves a moment of attention. In 1990, approximately 3.15 million people worldwide were living with Parkinson's disease. By 2021, that figure had reached 11.77 million, a 274% increase in three decades (GBD Study 2021, PMC, 2025). Projections from the Global Burden of Disease Study suggest that by 2050, more than 25 million people will be living with the condition worldwide (Ong et al., PubMed, 2025).

Most of this increase is explained by population ageing: as life expectancy rises, more people enter the decades where Parkinson's risk is highest. But ageing alone is insufficient as an explanation, and researchers are paying close attention to environmental factors.

A 2025 review published in The Lancet Neurology identified three classes of environmental toxicants with particularly robust links to Parkinson's disease: certain pesticides, the industrial solvent trichloroethylene (TCE) used in dry cleaning and manufacturing, and particulate air pollution (Tanner et al., 2025, The Lancet Neurology). Separately, a 2025 study found that people living within one to three miles of golf courses, where pesticide application is intensive, had a statistically elevated risk of developing Parkinson's disease, suggesting that indirect environmental exposure through air, water, and soil is relevant (APDA, 2025).

A 2025 Environmental Risk Factors review in Movement Disorders concluded that Parkinson's disease could, in a meaningful proportion of cases, be "largely preventable", a statement that, coming from a peer-reviewed movement disorders journal, carries considerable weight (Atterling Brolin et al., 2025).

What this means practically is not that every individual must buy an industrial water filtration system or live in a bubble. It means that understanding your environmental exposure history is a legitimate part of a comprehensive Parkinson's care conversation, and that dietary choices which reduce internal inflammation are not fringe medicine but an evidence-informed response to an evidence-based risk.

What the food research actually shows, and what It doesn't

Here is where precision becomes essential, and where this piece will be more careful than many you will read.

The research on food and Parkinson's disease operates across four distinct levels of evidence, and conflating them does a disservice to the people reading. The first level is risk reduction: observational studies showing that people who eat certain foods or patterns are less likely to develop Parkinson's disease. This is prevention data, and it does not automatically tell us what helps people already diagnosed. The second level is symptom management: evidence that certain dietary approaches improve specific non-motor symptoms such as constipation, fatigue, or sleep quality. The third level is disease modification: the question of whether diet can actually slow neuronal degeneration in human beings. This evidence, in the dietary domain, remains preliminary and contested. The fourth level is mechanistic: what happens in cells or animals when certain compounds are applied in laboratory conditions. This level generates hypotheses; it does not generate dietary prescriptions.

With that framework established, here is what the evidence actually shows

The Mediterranean dietary pattern, rich in vegetables, fruit, fish, olive oil, legumes, whole grains, and nuts, has the strongest observational evidence of any dietary pattern in Parkinson's. A 2024 meta-analysis of 12 studies found that the highest adherence to the Mediterranean diet was associated with a 25% lower odds of developing Parkinson's disease compared to the lowest adherence (OR: 0.75, 95% CI: 0.66–0.84) (Tong et al., ScienceDirect, 2024). This is prevention data. For people already diagnosed, a large observational study of 1,053 patients found that higher consumption of fresh vegetables, fruits, nuts, fish, and olive oil was associated with slower self-reported disease progression, while canned foods, sweetened drinks, and fried foods were associated with faster decline (Mischley et al., as reviewed in Cureus, 2024). This is observational data and cannot establish causation, but the direction of the findings is consistent across multiple independent cohorts.

A 2025 systematic review in Nutrients (MDPI) examining how to optimise dietary patterns for Parkinson's disease outcomes concluded that a modified Mediterranean-MIND approach, combining the Mediterranean diet's emphasis on olive oil, fish, and vegetables with the MIND diet's specific focus on berries and leafy greens, represents the most evidence-grounded dietary framework currently available. The review is careful to note this is not a proven disease-modifying intervention but rather a pattern associated with improved outcomes and better quality of life (MDPI/Nutrients, 2025).

One finding from this body of research is worth highlighting carefully. In one small cross-sectional study, women who reported the highest MIND diet adherence had a later average age of Parkinson's onset than those reporting the lowest adherence, with a difference of up to 17.4 years between the two groups (Agarwal et al., 2021). Because diet was assessed after diagnosis using recalled habits, and because the study was cross-sectional rather than prospective, this cannot be read as evidence that the MIND diet delayed Parkinson's by nearly two decades. Prospective research following people forward over time is needed before any causal conclusion is drawn. What the finding does suggest is that dietary pattern and disease timing are associated in ways that warrant serious investigation.

Small randomised trials have reported possible benefits from gut-targeted interventions, particularly for gastrointestinal symptoms such as constipation, as well as sleep quality and anxiety. One trial combining probiotics with vitamin D reported reductions in disease severity scores, though it is not possible from a combination intervention to attribute any benefit to probiotics alone (Tamtaji et al., as reviewed in Cureus, 2024). Products, study designs, and outcomes vary considerably across this literature, and the evidence base is not yet robust enough to support specific product recommendations. The direction of findings is encouraging; the certainty is not yet established.

Compounds research is taking seriously

Caffeine. One of the most replicated findings in Parkinson's nutritional epidemiology. Caffeine blocks adenosine receptors co-localised with dopamine receptors, directly influencing dopaminergic function. A 2024 study in Annals of Neurology found chronic caffeine intake associated with compensatory downregulation of the dopamine transporter, consistent with its observed risk-reduction effect (Saarinen et al., 2024). This is primarily prevention evidence; how much it benefits people already diagnosed is less established, and individual cardiovascular tolerance applies.

Curcumin. In cellular and animal models, curcumin inhibits alpha-synuclein aggregation and mitochondrial dysfunction (Hossain et al., 2025). Human trial results are inconsistent: at least one 60-person pilot failed to show efficacy on its principal outcomes (Belcaro et al., 2022), while a small number of enhanced-bioavailability formulations reported modest signals. Turmeric in food is safe and worth including. Supplementation is a different matter: piperine, commonly combined with curcumin to aid absorption, inhibits cytochrome P450 enzymes and can alter medication metabolism.

Green tea. EGCG, green tea's primary polyphenol, inhibits alpha-synuclein aggregation in cellular models and crosses the blood-brain barrier. Epidemiological studies associate regular consumption with reduced Parkinson's risk. Evidence in people already diagnosed has not been established in clinical trials (The Journal of Nutrition, 2025).

Berries. A 2025 preclinical study found berry supplementation improved motor performance, reduced dopaminergic cell loss, and decreased neuroinflammation in a validated Parkinson's mouse model (Tremblay et al., bioRxiv preprint, 2025, not yet peer-reviewed). Berries are among the richest sources of anthocyanins and quercetin, studied for gut microbiome modulation and anti-neuroinflammatory effects. They are also simply good food, and the absence of harm makes them worth eating regardless.

Omega-3 fatty acids. Found in oily fish, walnuts, and flaxseed, omega-3s support neuronal membrane integrity and have well-documented anti-inflammatory effects. Their role in the Mediterranean dietary pattern is structurally important, and their relevance to a condition driven partly by neuroinflammation is mechanistically sound. Clinical benefit specifically in Parkinson's remains an active research question.

Nicotinamide riboside (NR). This one surprises most people. NR is a form of vitamin B3 that the body uses to make NAD+, a molecule essential for mitochondrial energy production that declines with age. In Parkinson's disease, mitochondrial dysfunction is a central mechanism of neuronal loss. The NADPARK Phase 1 trial gave 30 newly diagnosed patients 1,000mg NR or placebo for 30 days. NR measurably increased brain NAD levels on neuroimaging, and those with elevated NAD showed altered cerebral metabolism and mild clinical improvement (Brakedal et al., Cell Metabolism, 2022). A 400-person Phase 2 trial, NOPARK, has since completed recruitment. This does not establish NR as a treatment, but the fact that a B vitamin precursor can measurably shift brain energy metabolism in Parkinson's patients in 30 days is a finding worth watching closely.

The gut: where the evidence is moving fastest

The gut microbiome of a person with Parkinson's disease differs measurably from that of someone without it. Reduced bacterial diversity, altered populations of short-chain fatty acid-producing bacteria, and increased intestinal permeability are consistently documented findings (Vieira de Moraes et al., 2025, Frontiers in Nutrition). These associations are well-replicated, though it remains difficult to fully separate the effects of the disease itself, constipation, medications such as levodopa, and diet from each other as contributing factors. Research into the gut-brain axis and alpha-synuclein propagation is advancing rapidly, and the microbiome is one of the most active areas of investigation in Parkinson's science.

The practical relevance: the gut microbiome is one of the most responsive biological systems in the body. Dietary fibre feeds the bacteria that produce short-chain fatty acids, which regulate intestinal permeability and have anti-inflammatory systemic effects. A high-fibre, diverse plant diet, the kind that underlies the Mediterranean approach, directly supports this microbial ecosystem.

Fecal microbiota transplantation (FMT) remains experimental. A clinical trial called GUT-PARFECT found a modest but statistically significant improvement in Parkinson's motor scores in patients receiving donor FMT compared to autologous FMT (Menozzi et al., 2025). This is early-stage evidence, and FMT is not a clinical recommendation. But its biological plausibility reinforces the case for microbiome-supportive dietary patterns as a legitimate, evidence-adjacent component of daily nutritional care.

Movement and food: two instruments playing the same score

No nutritional discussion of Parkinson's disease should omit exercise, because the two work through overlapping biological pathways and their combination appears more powerful than either alone.

Exercise stimulates the production of brain-derived neurotrophic factor (BDNF), a protein that supports the survival and growth of neurones. A 2024 systematic review confirmed that exercise training elevated BDNF, GDNF (Glial Cell Line-Derived Neurotrophic Factor), and related neurotrophic proteins in the nigrostriatal pathway, and upregulated dopaminergic signalling markers in animal models (PMC, 2025). In human clinical trials, aerobic, resistance, and multimodal exercise programmes consistently improve gait, balance, cognition, and quality of life in people with Parkinson's disease. Whether exercise modifies disease progression in humans remains an active research question rather than a settled conclusion, but the functional and symptomatic benefits are well-established and the biological rationale for neuroprotection is strong (Frontiers in Aging Neuroscience, 2025).

Current evidence supports early, sustained, multimodal exercise, combining aerobic, resistance, and balance training, as one of the most important non-pharmacological tools in Parkinson's care.

What an early diagnosis does not mean

This section is deliberately placed here, not at the end, because it is not a footnote. It is part of the diagnosis itself.

An early Parkinson's diagnosis does not mean that you caused this condition. Environmental factors, genetic susceptibility, age, and chance all interact in ways that are not within any individual's retrospective control. The evidence on pesticides and air pollution is population-level data, not a verdict on your choices.

It does not mean that every dietary decision will determine your disease course. Parkinson's disease is variable and individual. Nutrition can support your health, your gut, your energy, and your non-motor symptom burden. It cannot guarantee a particular trajectory, and anyone suggesting otherwise is overstepping the evidence.

It does not mean that supplements are automatically safe. Interactions vary by supplement and medication. As noted above, piperine used to enhance curcumin absorption can affect drug metabolism; high-dose fish oil can affect anticoagulation; some probiotic products may not be appropriate alongside certain immunomodulatory treatments. The specific risks depend on what you are taking and which medications you are on. Every supplement decision warrants a conversation with your neurologist or pharmacist before you begin.

It does not mean you should delay or deprioritise medication. Levodopa and other dopaminergic therapies have a robust, decades-long evidence base for symptom management that no dietary intervention approaches. For people taking levodopa, protein timing across the day is a well-established practical consideration: high-protein meals can compete with levodopa absorption in the small intestine, and a registered nutritional therapist familiar with Parkinson's will help you navigate this individually. Food and medication are partners, not competitors.

It does not mean that loss of smell or constipation is a diagnosis. These symptoms are common and have many causes. One symptom in isolation is not Parkinson's.

And it does not mean that the next chapter has already been written.

What you can start doing now: a practical frame

Based on what the evidence currently supports, here is a practical framing, not a protocol, because individual needs vary enormously, but a direction.

Move the plate toward a Mediterranean pattern: more vegetables, fruit, legumes, fish, olive oil, and nuts; less processed food, fried food, and sugar. This is the dietary approach with the strongest and most consistent evidence across multiple outcomes relevant to Parkinson's disease.

Feed your gut daily. Diversity of plant fibre is the single most impactful thing most people in Western countries could do for their microbiome. Aiming for a wide variety of plant foods across the week, including vegetables, fruits, legumes, wholegrains, nuts, and seeds, is a diversity goal used in gut health research. It is not a validated Parkinson's-specific protocol, but greater dietary diversity is consistently associated with more diverse and beneficial microbiome composition.

Protect your sleep, and understand why it matters at a biological level that most Parkinson's consultations do not address. The brain has its own waste-clearance system, called the glymphatic system, that is most active during deep sleep. Animal studies have found that the brain's interstitial space expands significantly during sleep, facilitating the clearance of metabolic waste including protein aggregates. While the specific relevance to alpha-synuclein clearance in humans with Parkinson's disease has not been directly established, research published in SLEEP framed glymphatic dysfunction as a plausible disease-modifying mechanism in Parkinson's and sleep optimisation as a promising therapeutic direction worth investigating (Holter et al., 2024, SLEEP). The clinical case for prioritising sleep quality in Parkinson's is strong on symptom grounds alone - and the glymphatic hypothesis adds a compelling biological rationale to pursue it.

Reduce where you can your exposure to pesticides and industrial solvents, through food choices, domestic products, and awareness of occupational or local environmental exposure.

Maintain your weight and muscle mass. Unintentional weight loss and muscle wasting are significant concerns in Parkinson's disease and negatively affect quality of life, balance, and medication response. NICE guidelines specifically advise against reducing total daily protein in people with Parkinson's disease. Where protein distribution around levodopa doses becomes relevant, because high-protein meals can compete with levodopa absorption, this should be managed in close coordination with your prescribing team, not by reducing overall protein intake.

Work with a Registered Nutritional Therpaist. Nutrition in Parkinson's is most powerful when it is personalised, co-ordinated with your medication schedule, and supported by someone who understands the specific nutritional considerations of this condition.

The man his neurologist could not keep up with

In the world of Parkinson's research, case studies involving individuals are inevitably limited as evidence. But sometimes a single person's story illuminates what the biology is actually capable of, in a way that no population average can.

John Pepper was diagnosed with Parkinson's disease in 1992. More than two decades later, his neurologist confirmed he still had the disease. Norman Doidge, the Canadian psychiatrist and author of The Brain's Way of Healing, devoted an entire chapter to Pepper's story after observing him personally and found him to be a man who, through extraordinary personal effort, was functioning at a level that surprised observers.

What the neurologist and Doidge both had to contend with, walking alongside Pepper, was the fact that they could not keep up. Pepper walked fast, with full arm swing, fluid movement, and none of the characteristic shuffle or freezing that clinicians associate with Parkinson's disease. Doidge described working hard to match the pace of a man whose movement, in that moment, bore little visible resemblance to the condition on his medical record.

Pepper's approach centred on fast, conscious walking: deliberately paced, intentional aerobic exercise in which he paid deliberate attention to gait, arm swing, and posture. Combined with weight training, an MAO-B inhibitor, and a consistent daily discipline, this became the structure of his daily life for decades.

It is important to be clear about what this story is and is not. John Pepper's account has not been assessed through controlled measurement or independent longitudinal clinical evaluation. It is a personal story, documented in a popular book, and it cannot establish what biological mechanisms were or were not responsible for his functional state. It should not be read as proof of neuroplastic rerouting or evidence that Parkinson's disease was reversed. What it is, honestly, is a story that many people living with Parkinson's find motivating, and motivation, when it drives sustained daily aerobic exercise with proven symptomatic benefits, has real value. The science of exercise and Parkinson's is robust enough to stand on its own without needing an anecdote to support it. Pepper's story is simply a reminder that effort, sustained over years, is worth beginning.

The door that opened

There is a particular kind of courage that comes after a diagnosis like this, not the courage of certainty, but the courage of action without guarantees. The science does not offer you certainty. But it does offer you agency. It offers you a growing, serious, peer-reviewed body of evidence that what you eat, how you move, and how you care for your gut has measurable effects on how you feel and function with Parkinson's disease.

That is not a small thing. In a condition where so much feels outside your control, that is, in fact, an extraordinary thing.

The neurones that remain are alive. They are embedded in a biological environment that you help create every day. The science doesn't yet tell us that food can stop neurodegeneration. It does tell us, with increasing clarity, that the environment you build around those neurones, through diet, exercise, sleep, and gut health, shapes the quality of life you live within this diagnosis.

A diagnosis is not a destiny. It is a starting point. And the right support, at the right time, changes what the next chapter looks like.

Working with Melody: Parkinson's Nutritional Therapy

If you have recently received a Parkinson's diagnosis, one of the most practical steps alongside your neurological care is to work with a nutritional therapist who has specific expertise in Parkinson's disease.

Melody is a registered Nutritional Therapist specialising in Parkinson's disease. She works with clients to build dietary and lifestyle approaches grounded in current evidence, focusing on gut microbiome support, nutritional adequacy, symptom management (including constipation, fatigue, sleep, and weight maintenance), and the specific management of protein intake for people taking levodopa.

Melody works in partnership with your clinical team, not in place of it. Her role is to translate the emerging science of Parkinson's nutrition into a practical, personalised plan that works with your medications, your lifestyle, and your individual needs.

Book an initial consultation with Melody

🧩 Connect with us

For research updates, practical tips, and ongoing inspiration, follow us on Instagram:

👉 @drkirstielawton

👉 @nutritionandthebrain

👉 @younutritionkids

Stay curious. Stay hopeful. Support your brain. 🧠

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult with a qualified, registered medical doctor (MD) for diagnosis and treatment decisions.

References

Brakedal, B., et al. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism, 35(4). https://www.cell.com/cell-metabolism/fulltext/S1550-4131(22)00045-6

Doidge, N. (2015). The Brain's Way of Healing. Viking Press. [Chapter on John Pepper and conscious walking in Parkinson's disease.

Holter, K.E., et al. (2024). Glymphatic system, sleep, and Parkinson's disease: interconnections, research opportunities, and potential for disease modification. SLEEP, 48(1). https://academic.oup.com/sleep/article/48/1/zsae251/7840739

Atterling Brolin, K., et al. (2025). Environmental Risk Factors for Parkinson's Disease: A Critical Review and Policy Implications. Movement Disorders, 40(3). https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.30067

GBD 2021 Parkinson's Disease Collaborators (2025). Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021. The Lancet Neurology. https://pmc.ncbi.nlm.nih.gov/articles/PMC11757241/

Belcaro, G., et al. (2022). Curcumin and Boswellia in Parkinson's disease: a pilot randomised controlled trial. International Journal of Molecular Sciences / ScienceDirect. https://www.sciencedirect.com/science/article/pii/S0303846722001810

Hossain, M.S., et al. (2025). Curcumin as a potential therapeutic agent for Parkinson's disease: a systematic review. Neurochemistry International. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052530/

Menozzi, E., et al. (2025). The Gut-Brain Axis in Parkinson Disease: Emerging Concepts and Therapeutic Implications. Movement Disorders Clinical Practice. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mdc3.70029

Mischley, L.K. (2025). Nutrition and Parkinson's Disease. American Parkinson Disease Association. https://www.apdaparkinson.org/wp-content/uploads/2025/01/Nutrition-Parkinson-PDF.pdf

Kelemen, M., et al. (2025). Beyond MIND and Mediterranean Diets: Designing a Diet to Optimize Parkinson's Disease Outcomes. Nutrients, 17(14). https://www.mdpi.com/2072-6643/17/14/2330

Ong, M.X., et al. (2025). Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. https://pubmed.ncbi.nlm.nih.gov/40044233/

Orso, B., Brosse, S., Frasnelli, J., & Arnaldi, D. (2024). Opportunities and Pitfalls of REM Sleep Behavior Disorder and Olfactory Dysfunction as Early Markers in Parkinson's Disease. Journal of Parkinson's Disease, 14(2). https://journals.sagepub.com/doi/10.3233/JPD-230348

Hirsch, M.A., et al. (2025). Effects of exercise training on nigrostriatal neuroprotection in Parkinson's disease: a systematic review. npj Parkinson's Disease. https://pmc.ncbi.nlm.nih.gov/articles/PMC11752748/

Rodriguez, T.N., Smeyne, R.J., & Smeyne, M. (2026). Neurobiology of exercise in Parkinson's disease. Frontiers in Aging Neuroscience. https://doi.org/10.1177/1877718X261452869

Saarinen, M., et al. (2024). Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease. Annals of Neurology. https://onlinelibrary.wiley.com/doi/10.1002/ana.26957

Schrag, A., et al. (2015). Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. The Lancet Neurology, 14(1), 57–64.

Subramanian, I., et al. (2026). A Holistic Wellness Prescription for Parkinson's Disease: Evidence-Based Perspectives and Unmet Needs. Movement Disorders Clinical Practice. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mdc3.70381

Tanner, C.M., et al. (2025). Environmental toxicants and Parkinson's disease: recent evidence, risks, and prevention opportunities. The Lancet Neurology. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00287-X/abstract

Tong, Y., et al. (2024). Association between Mediterranean diet adherence and Parkinson's disease: a systematic review and meta-analysis. ScienceDirect / Journal of the Neurological Sciences. https://pubmed.ncbi.nlm.nih.gov/39693849/

Tosefsky, K.N., et al. (2024). The Role of Diet in Parkinson's Disease. Journal of Parkinson's Disease. https://journals.sagepub.com/doi/10.3233/JPD-230264

Agarwal, P., et al. (2021). MIND and Mediterranean Diets Associated with Later Onset of

Parkinson's Disease. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248352/

Tremblay, C., et al. (2025). From berries to brain: Assessing the impact of (poly)phenols in the MPTP mouse model of Parkinson's disease. bioRxiv [preprint, not yet peer-reviewed]. https://www.biorxiv.org/content/10.1101/2025.08.16.670034.full.pdf

Vieira de Moraes, D., et al. (2025). Microbiome-based therapies for Parkinson's disease. Frontiers in Nutrition. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1496616/full

Wang, X., et al. (2024). Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease. JAMA Neurology. https://pubmed.ncbi.nlm.nih.gov/38513162/

Zhang, Y., et al. (2025). Implication of nutrition in severity of symptoms and treatments in quality of life in Parkinson's disease: a systematic review. Frontiers in Nutrition, 11. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1434290/full

NICE (2017, updated 2023). Parkinson's disease in adults: diagnosis and management. Guideline NG71. https://www.nice.org.uk/guidance/ng71/chapter/Recommendations

An early Parkinson's diagnosis: what it could mean for care, and what it doesn't

Before the tremor: your body was already sending signals

What actually changes in the brain at early diagnosis

What actually changes in the brain at early diagnosis

Why Parkinson's is rising, and what the environment has to do with It

What the food research actually shows, and what It doesn't

With that framework established, here is what the evidence actually shows

Compounds research is taking seriously

The gut: where the evidence is moving fastest

Movement and food: two instruments playing the same score

What an early diagnosis does not mean

What you can start doing now: a practical frame

The man his neurologist could not keep up with

The door that opened

Working with Melody: Parkinson's Nutritional Therapy

References

Recent Posts

Comments